Navigation Links
Scientists identify specific markers that trigger aggressiveness of liver cancer
Date:10/20/2009

Hepatocellular carcinoma (HCC) or primary liver cancer forms in the epithelial tissue of the liver and is most commonly caused by the hepatitis B virus (HBV) or hepatitis C virus (HCV). In the U.S., the National Cancer Institute (NCI) estimates that 15,000 men and 6,000 women are diagnosed with HCC each year. Worldwide, HCC accounts for 632,000 cases with the highest regions being Western Pacific and Africa according to a 2004 World Health Organization (WHO) report.

Researchers from Taipei Veterans General Hospital investigated the molecular mechanisms of HCC, one of the most common tumors found in Taiwan and largely caused by the high prevalence (15%-20%) of HBV in the country. The study, funded in part by a grant from the National Science Council, is the first to provide a comprehensive profile of multiple Epithelial-Mesenchymal Transition (EMT) markers and to demonstrate that Snail and Twist, but not Slug, are the major inducers of EMT in HCC. Results of the study are published in the November issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

EMT is critical in the development of invasiveness and metastatic potential of human cancers, and described as process where epithelial cells no longer adhere to one another, taking on fibroblastic properties. The EMT process is initiated by suppression of E-cadherin function through the major EMT regulators (Snail, Slug, and Twist). E-cadherin (calcium dependent adhesion molecules) is a type of protein found in the epithelial cells that ensure tissue cells bind together. When E-cadherin function is lost, cancer is able to progress and metastasize.

Professor Jaw-Ching Wu and colleagues obtained samples of primary HCC with adjacent non-tumorous liver tissues from 123 patients who had hepatic resection surgery between 1990 and 2002 at Taipei Veterans General Hospital. Reduced E-cadherin function was observed in 60.2% of patients. "We found a significant decrease in cancer-free intervals and overall survival for those patients who had a reduction in E-cadherin function," explained Dr. Wu. A downregulated expression of E-cadherin was also associated with large tumor size and multi-nodular tumors.

Results show that co-expression Snail and Twist (transcription factors or proteins that control when genes are switched on or off) indicates the worst prognosis for HCC patients. "Our research is the first to prove that the two proteins (Snail and Twist) work independently, but together promote EMT," noted Dr. Wu.

According to the study, overexpression of Twist is correlated with HCV-related HCC, partially explaining the highly invasive behavior and poor prognosis for patients with this form of liver cancer. Dr Wu added, "Our results provide essential information for determining HCC prognosis in patients and identifies possible new treatments for future HCC management."


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Connance, a leading provider of ... how predictive analytics drive reimbursement optimization, with a focus on denial management and ... , “The traditional approach to denied and underpaid claims leaves money on the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Fresenius Vascular Care, a national network of ... treat and manage a wide range of vascular conditions, has today announced its new ... 65 centers represented by more than 40 local brands, a phased rollout of the ...
(Date:6/20/2017)... SAN DIEGO, California (PRWEB) , ... June 20, ... ... modern product documentation and help content solutions for the enterprise, is proud to ... web properties, including CRM, e-commerce, ticketing systems, company websites, and more to provide ...
(Date:6/20/2017)... JEFFERSON HILLS, PA (PRWEB) , ... June 20, ... ... now available at Allegheny Health Network’s (AHN) Jefferson Hospital is providing physicians with ... 1.5T, 48-channel scanner provides higher-resolution images than traditional MRIs, enabling doctors to get ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... industry has been selected as the partner of choice by Amtrak to fulfill ... service that provides medium- and long-distance intercity service in the contiguous United States. ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... Cincinnati location of Diplomat Specialty Infusion ... been awarded a Top Workplaces 2017 honor by ... on an employee survey administered by WorkplaceDynamics, LLC, a research ... measures several aspects of workplace culture, including alignment, execution, and ... ...
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
Breaking Medicine Technology: